Literature DB >> 22693310

Imaging of multiple myeloma and related plasma cell dyscrasias.

Ronald C Walker1, Tracy L Brown, Laurie B Jones-Jackson, Lorraine De Blanche, Twyla Bartel.   

Abstract

Multiple myeloma (MM) is an incurable plasma cell malignancy of the bone marrow. MM has 3 components: diffuse marrow infiltration, focal bone lesions, and soft-tissue (extramedullary) disease. The hallmark biomarker in blood or urine is a monoclonal immunoglobulin, the monoclonal protein. Waldenstrom macroglobulinemia is a similar disease with secretion of IgM. Staging is classically performed with the 1975 Durie-Salmon system, which includes conventional radiographs. Recently updated, the Durie-Salmon Plus staging system includes CT, MRI, and (18)F-FDG PET/CT. The hallmark radiographic lesion of symptomatic MM is a well-demarcated, focal osteolytic bone lesion. The number of focal bone lesions correlates inversely with outcome. Extramedullary disease is typically an aggressive, poorly differentiated form of MM that confers inferior outcome, with median survival of less than 1 y if present at diagnosis. Achievement of a complete response on (18)F-FDG PET before stem-cell transplantation correlates with a superior outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22693310     DOI: 10.2967/jnumed.111.098830

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  23 in total

1.  Minimal residual disease in multiple myeloma.

Authors:  Nikhil C Munshi; Kenneth C Anderson
Journal:  J Clin Oncol       Date:  2013-06-03       Impact factor: 44.544

2.  Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states.

Authors:  F Joseph Simeone; Joel P Harvey; Andrew J Yee; Elizabeth K O'Donnell; Noopur S Raje; Martin Torriani; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2018-09-14       Impact factor: 2.199

3.  PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.

Authors:  Christos Sachpekidis; Hartmut Goldschmidt; Dirk Hose; Leyun Pan; Caixia Cheng; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

Review 4.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

5.  Pretreatment 18F-FDG PET/CT combined with quantification of clonal circulating plasma cells as a potential risk model in patients with newly diagnosed multiple myeloma.

Authors:  Yoshiaki Abe; Kentaro Narita; Hiroki Kobayashi; Akihiro Kitadate; Daisuke Miura; Masami Takeuchi; Eri O'uchi; Toshihiro O'uchi; Kosei Matsue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-28       Impact factor: 9.236

6.  Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma.

Authors:  Christos Sachpekidis; Jens Hillengass; Hartmut Goldschmidt; Hoda Anwar; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

Review 7.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

8.  Clinical value of ¹¹C-methionine PET/CT in patients with plasma cell malignancy: comparison with ¹⁸F-FDG PET/CT.

Authors:  Yuji Nakamoto; Kensuke Kurihara; Masatoshi Nishizawa; Kouhei Yamashita; Koya Nakatani; Tadakazu Kondo; Akifumi Takaori-Kondo; Kaori Togashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236

9.  Multimodal imaging and clinical characteristics of bone lesions in POEMS syndrome.

Authors:  Xiao-Feng Shi; Shu-Dong Hu; Jun-Min Li; Xian-Fu Luo; Zhang-Biao Long; Yan Zhu; Xiao-Dong Xi
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 10.  ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.

Authors:  Franco Dammacco; Giuseppe Rubini; Cristina Ferrari; Angelo Vacca; Vito Racanelli
Journal:  Clin Exp Med       Date:  2014-09-14       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.